To read the full story, subscribe or sign in.

Asceneuron raises $100M for OGA inhibitor work in Alzheimer’s

July 16, 2024

Asceneuron SA has raised $100 million in an oversubscribed series C to take its lead small molecule, ASN-51, into phase II, with aim of demonstrating it prevents the formation of tau tangles and slows the progression of Alzheimer’s disease.

BioWorld Financings Neurology/psychiatric Small molecule Series C Europe

Today's news in brief

BioWorld

BioWorld briefs for Aug. 22, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Aug. 21, 2025.

FDA approved icons and medical professional

Ionis gets approval for preventing attacks in rare and genetic HAE

BioWorld

In Ionis Pharmaceuticals Inc.’s second U.S. FDA approval in under a year, the agency approved Dawnzera (donidalorsen) as a prophylactic therapy in the rare and...

Elderly woman holding illustration of brain with missing puzzle piece

Marvel Biotechnology’s MB-204 as therapeutic agent for Alzheimer’s disease

BioWorld Science

Phosphorylation of the protein Tau is a key post-translational feature in tauopathies like Alzheimer’s disease (AD), which leads to microtubule dysfunction and...

Wooden blocks spelling TARIFFS with a U.S. flag on top, placed on a map of Europe

EU, US lock in 15% max Rx tariff, no relief for medtech

BioWorld

No matter what level of tariff the Trump administration ends up imposing on biopharmaceuticals across the world, drugs and their precursors originating in the EU...